MDR1, P-gp, ABCB1: Why One Protein Has Three Names
MDR1, P-glycoprotein, and ABCB1 are not three different things you need to learn. They’re three names for the same single player, described from different angles — like calling one person by their legal name, their nickname, and their job title.
The distinction that matters is gene versus protein. ABCB1 is the official gene name (it stands for “ATP-Binding Cassette subfamily B member 1”). MDR1 — short for “Multidrug Resistance 1” — is the older, still widely used name for the same gene. So when a genetic test or pharmacogenomic report lists ABCB1 or MDR1, it’s pointing at the instruction set in the DNA.
P-glycoprotein (P-gp) is what those instructions build: the actual protein, the working machine your cells produce by reading the gene. Gene = blueprint; protein = the thing the blueprint makes.
This is why the naming feels chaotic. A veterinary genetic panel might say “MDR1,” a human drug-interaction warning might cite “P-gp,” and a clinical pharmacogenomic report might use “ABCB1” — but all three circle the same biology. Spot any of them and you’re in the right place.
Why does this one protein earn three names and a dedicated explainer? Because P-gp acts as a gatekeeper, controlling which drugs get pushed out of cells — and that single job explains both why a medication fails and why it can turn dangerous.
What the MDR1 Protein Actually Does in the Body
Picture a nightclub bouncer stationed at the door of every important cell in the body. That’s what the MDR1 protein does. It sits embedded in cell membranes and acts as a one-way pump, grabbing foreign molecules that drift inside and shoving them back out before they can cause trouble. It’s an ancient, built-in defense system that decides what gets to stay and what gets evicted.
P-gp isn’t spread evenly. It’s concentrated where the body most needs to control what passes through: the lining of your gut, the liver, the kidneys, and — most importantly — the blood-brain barrier, the tight wall of cells guarding the brain. In those locations, the pump’s job is protective. It keeps toxins, waste, and a long list of drugs from accumulating in sensitive tissues, especially neural tissue that doesn’t tolerate chemical intruders well.
Here’s where it gets practical. If that pump is missing, defective, or chemically blocked, the bouncer walks off the job. Substances that should have been turned away at the door instead flood in and build up where they don’t belong — frequently the brain. A drug dosed at a perfectly normal level can then reach concentrations high enough to cause serious neurological effects. That single mechanism is the thread connecting everything else in this article, whether you’re reading about people or dogs.
Why MDR1 Matters: Drug Failure vs. Drug Toxicity
Here’s the twist that makes MDR1 worth understanding: the same protein can cause two opposite problems, and which one you’re dealing with depends entirely on whether you have too much of it or too little.
When that bouncer works too hard, you get the drug failure problem. Cancer cells, for example, can crank up their P-gp production and pump chemotherapy drugs back out before the medicine can do its job — one of the classic reasons a tumor stops responding to treatment. The drug isn’t weak; it’s being evicted.
Flip that around and you get the drug toxicity problem. When there’s too little working P-gp — say, because of a genetic mutation — the bouncer isn’t there to keep drugs out of sensitive places like the brain. Medications that should’ve been turned away at the door flood in and accumulate to dangerous levels, triggering severe side effects from an otherwise normal dose.
So the stakes pull in opposite directions: a medication that quietly fails, or one that quietly poisons. Which branch matters to you depends on the context you arrived from — so the next two sections split cleanly into the dog scenario and the human scenario. Jump to yours.
MDR1 in Dogs: The Inherited Sensitivity in Herding Breeds
If your dog is a Collie, Australian Shepherd, or related breed, that cellular bouncer may not be doing its job — and that can turn a routine dewormer into a medical emergency. The culprit is a mutation in the MDR1 gene (also written as ABCB1). Normally this gene tells the body how to build working P-glycoprotein, the pump that keeps certain drugs out of the brain. When the gene is mutated, the dog produces little or no functional P-gp, so drugs that should be blocked at the blood-brain barrier leak straight into the central nervous system.
The result is neurological toxicity — disorientation, drooling, tremors, dilated pupils, trouble walking, and in severe cases seizures, coma, or death. Drugs like ivermectin (in high doses), loperamide (Imodium), and certain anesthetics and chemotherapy agents are common triggers.
The mutation is most common in herding breeds:
- Collies — roughly 70% carry at least one copy
- Australian Shepherds and Aussie mixes
- Shetland Sheepdogs
- Long-haired Whippets, Old English Sheepdogs, and many mixed-breed dogs with herding ancestry
Genetic tests report your dog as one of three results. Two normal copies means no extra risk. One copy (intermediate) means reduced P-gp — your dog can usually handle standard doses but may need adjustments for high-risk drugs. Two copies (high-risk) means essentially no working pump, and certain drugs should be avoided or carefully dose-reduced. Always share the result with your vet before any new medication.
Drugs That Are Risky for MDR1-Affected Dogs
The single most famous danger is ivermectin, the drug at the center of the old “white feet, don’t treat” warning for herding breeds. But ivermectin is only one member of a larger family called macrocyclic lactones, which includes milbemycin, moxidectin, and selamectin. Dose is everything here. The tiny amounts in monthly heartworm preventives are generally safe even for MDR1-affected dogs, because the dose is calibrated low. The danger comes from high-dose exposure — most often when a dog gets into concentrated livestock dewormer formulated for horses or cattle.
The other big offenders to know:
- Loperamide (the active ingredient in human anti-diarrheal products like Imodium) — never share these with an affected dog.
- Certain anesthetics and sedatives, including acepromazine and butorphanol, which can cause prolonged or exaggerated effects.
- Several chemotherapy agents, such as vincristine and doxorubicin.
Red flags to avoid
- Giving any livestock or horse dewormer without exact vet-calculated dosing
- Sharing human anti-diarrhea medication
- Scheduling sedation, dental work, or chemotherapy without telling the vet about the MDR1 status
The reassuring part: an MDR1-affected dog can live a completely normal, full-length life. The mutation doesn’t make your dog sick on its own — it changes which drugs and doses are safe. Once your vet has that one piece of information, they can adjust nearly everything around it.
MDR1 and P-gp in Human Medicine
If you arrived from a human pharmacogenomic report instead, the story is different. There’s no equivalent of the “MDR1 mutant” diagnosis that dogs get. Nobody hands you a result saying you’re dangerously sensitive to a specific dewormer. The same protein — P-glycoprotein, encoded by the ABCB1 gene — does the same basic job in your body, but the clinical story is much messier and less defined.
In people, P-gp acts as a gatekeeper in your gut lining, kidneys, liver, and the blood-brain barrier. It actively pumps certain drugs back out before they’re absorbed or into the brain, which affects how much medication reaches your bloodstream. That matters in three real situations:
- Absorption: P-gp can limit how much of an oral drug gets in.
- Drug interactions: Some substances are inhibitors (like the compounds in grapefruit juice, or drugs such as verapamil) that block P-gp and raise other drugs’ levels, while inducers (like rifampin or St. John’s wort) ramp it up and weaken them.
- Chemotherapy resistance: Tumor cells can overexpress P-gp and pump chemo back out, blunting treatment.
If you see an ABCB1 result on a pharmacogenomic report, treat it cautiously. As of 2026, these variants are still considered weak, inconsistent predictors of drug response — the evidence isn’t strong enough to override clinical judgment. Always run interactions and results past your prescriber or pharmacist.
What to Do With an MDR1 Test Result or Warning
A test result sitting in an inbox or a warning label on a pill bottle does nothing on its own — what matters is the conversation you have next. Here’s how to turn that piece of jargon into an actual safeguard.
If You Have a Dog’s MDR1 Result
Don’t try to decode the genotype yourself. Instead:
- Share the result with your vet and confirm it’s added to your pet’s permanent medical record, not just filed in a drawer.
- Ask before every new medication or procedure — especially dewormers (ivermectin), certain anti-diarrheals (loperamide), and anesthesia for surgery.
- Test at-risk breeds before treatment. Washington State University’s veterinary lab, which pioneered the test, recommends screening herding breeds proactively rather than after a bad reaction. A panel typically runs $60–$80.
If You’ve Seen an ABCB1 or P-gp Note
This usually appears in a drug-interaction warning or a pharmacogenomic report. Bring it to your prescriber or pharmacist — don’t self-adjust doses or stop a medication based on it. They can weigh it against your full picture, since P-gp status rarely changes treatment on its own.
When to Escalate
Loop in a professional promptly if you (or your dog) experience unexplained side effects on a new drug, have surgery coming up, or are starting chemotherapy. In every case, a result only means something with clinical context behind it.
Does Dog MDR1 Information Apply to Humans (and Vice Versa)?
Here’s the question that probably brought you to this section: if it’s the same protein, can you read the dog list and apply it to yourself — or the human warnings and apply them to your dog? Short answer: no, and doing so could lead you badly astray.
The biology genuinely connects the two. It’s the same gene family (ABCB1) producing the same pump (P-glycoprotein) doing the same job — escorting drugs out of cells and guarding the brain. That shared machinery is why the term shows up in both vet clinics and pharmacology reports. But the clinical situations are entirely different.
In dogs, the inherited MDR1 mutation is a defined, well-characterized problem with a clear list of high-risk drugs (ivermectin, loperamide, certain anesthetics) and a straightforward genetic test. In humans, P-gp matters mostly for drug interactions, chemotherapy resistance, and dosing nuance — there’s no routine “MDR1 sensitivity diagnosis” the way there is for herding breeds.
So treat the two as separate playbooks:
- Don’t use a canine drug-danger list to make decisions about your own medications.
- Don’t assume a human drug-interaction warning means anything about what’s safe for your dog.
The biology links them, but the right action depends entirely on the species — and the professional. Talk to your physician or pharmacist for human decisions, and your veterinarian for canine ones.
